Search Results - "COOPER, Wendy"

Lessons and opportunities from improved understanding of global lung cancer histological subtypes by Cooper, Wendy A

“…In a population-based study of variations in lung cancer incidence by histological subtype in 2020, Yanting Zhang and colleagues1 have provided, for the first…”
Get full text

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015 by Nicholson, Andrew G, Tsao, Ming S, Beasley, Mary Beth, Borczuk, Alain C, Brambilla, Elisabeth, Cooper, Wendy A, Dacic, Sanja, Jain, Deepali, Kerr, Keith M, Lantuejoul, Sylvie, Noguchi, Masayuki, Papotti, Mauro, Rekhtman, Natasha, Scagliotti, Giorgio, van Schil, Paul, Sholl, Lynette, Yatabe, Yasushi, Yoshida, Akihiko, Travis, William D

“…The 2021 WHO Classification of Thoracic Tumours was published earlier this year, with classification of lung tumors being one of the chapters. The principles…”
Get more information

Rethinking Biomarkers for Combination Chemoimmunotherapy by Cooper, Wendy A, John, Thomas

Get more information

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study by van Zandwijk, Nico, Pavlakis, Nick, Kao, Steven C, Linton, Anthony, Boyer, Michael J, Clarke, Stephen, Huynh, Yennie, Chrzanowska, Agata, Fulham, Michael J, Bailey, Dale L, Cooper, Wendy A, Kritharides, Leonard, Ridley, Lloyd, Pattison, Scott T, MacDiarmid, Jennifer, Brahmbhatt, Himanshu, Reid, Glen

“…TargomiRs are minicells (EnGeneIC Dream Vectors) loaded with miR-16-based mimic microRNA (miRNA) and targeted to EGFR that are designed to counteract the loss…”
Get full text

The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer by Bremnes, Roy M, Busund, Lill-Tove, Kilvær, Thomas L, Andersen, Sigve, Richardsen, Elin, Paulsen, Erna Elise, Hald, Sigurd, Khanehkenari, Mehrdad Rakaee, Cooper, Wendy A, Kao, Steven C, Dønnem, Tom

“…A malignant tumor is not merely an accumulation of neoplastic cells, but constitutes a microenvironment containing endothelial cells, fibroblasts, structural…”
Get more information

Predictive and prognostic biomarkers in solid tumours by Cooper, Wendy A., Tan, Puay Hoon

Get full text

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer by Hendry, Shona, Byrne, David J, Wright, Gavin M, Young, Richard J, Sturrock, Sue, Cooper, Wendy A, Fox, Stephen B

“…Four different programmed death ligand 1 immunohistochemical assays are approved or in development as companion or complementary diagnostics to different…”
Get more information

Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation by Paver, Elizabeth C., Cooper, Wendy A., Colebatch, Andrew J., Ferguson, Peter M., Hill, Sean K., Lum, Trina, Shin, Joo-Shik, O'Toole, Sandra, Anderson, Lyndal, Scolyer, Richard A., Gupta, Ruta

“…Immunotherapy with checkpoint inhibitors is well established as an effective treatment for non-small cell lung cancer and melanoma. The list of approved…”
Get full text

Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry by Jo, Helen E, Glaspole, Ian, Grainge, Christopher, Goh, Nicole, Hopkins, Peter M A, Moodley, Yuben, Reynolds, Paul N, Chapman, Sally, Walters, E Haydn, Zappala, Christopher, Allan, Heather, Keir, Gregory J, Hayen, Andrew, Cooper, Wendy A, Mahar, Annabelle M, Ellis, Samantha, Macansh, Sacha, Corte, Tamera J

“…7The prevalence of idiopathic pulmonary fibrosis (IPF), a fatal and progressive lung disease, is estimated at 1.25-63 out of 100 000, making large population…”
Get full text

Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer by Cooper, Wendy A, Russell, Prudence A, Cherian, Maya, Duhig, Edwina E, Godbolt, David, Jessup, Peter J, Khoo, Christine, Leslie, Connull, Mahar, Annabelle, Moffat, David F, Sivasubramaniam, Vanathi, Faure, Celine, Reznichenko, Alena, Grattan, Amanda, Fox, Stephen B

“…Reliable and reproducible methods for identifying PD-L1 expression on tumor cells are necessary to identify responders to anti-PD-1 therapy. We tested the…”
Get full text

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy by Travis, William D, Dacic, Sanja, Wistuba, Ignacio, Sholl, Lynette, Adusumilli, Prasad, Bubendorf, Lukas, Bunn, Paul, Cascone, Tina, Chaft, Jamie, Chen, Gang, Chou, Teh-Ying, Cooper, Wendy, Erasmus, Jeremy J, Ferreira, Carlos Gil, Goo, Jin-Mo, Heymach, John, Hirsch, Fred R, Horinouchi, Hidehito, Kerr, Keith, Kris, Mark, Jain, Deepali, Kim, Young T, Lopez-Rios, Fernando, Lu, Shun, Mitsudomi, Tetsuya, Moreira, Andre, Motoi, Noriko, Nicholson, Andrew G, Oliveira, Ricardo, Papotti, Mauro, Pastorino, Ugo, Paz-Ares, Luis, Pelosi, Giuseppe, Poleri, Claudia, Provencio, Mariano, Roden, Anja C, Scagliotti, Giorgio, Swisher, Stephen G, Thunnissen, Erik, Tsao, Ming S, Vansteenkiste, Johan, Weder, Walter, Yatabe, Yasushi

“…Currently, there is no established guidance on how to process and evaluate resected lung cancer specimens after neoadjuvant therapy in the setting of clinical…”
Get more information

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma by Kao, Steven C, Cheng, Yuen Yee, Williams, Marissa, Kirschner, Michaela B, Madore, Jason, Lum, Trina, Sarun, Kadir H, Linton, Anthony, McCaughan, Brian, Klebe, Sonja, van Zandwijk, Nico, Scolyer, Richard A, Boyer, Michael J, Cooper, Wendy A, Reid, Glen

“…The upregulation of programmed death ligand 1 (PD-L1) is found in many cancers and contributes to evasion of the host's immune defense. In malignant pleural…”
Get more information

Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA by Hudecova, Irena, Smith, Christopher G, Hänsel-Hertsch, Robert, Chilamakuri, Chandra S, Morris, James A, Vijayaraghavan, Aadhitthya, Heider, Katrin, Chandrananda, Dineika, Cooper, Wendy N, Gale, Davina, Garcia-Corbacho, Javier, Pacey, Simon, Baird, Richard D, Rosenfeld, Nitzan, Mouliere, Florent

“…Current evidence suggests that plasma cell-free DNA (cfDNA) is fragmented around a mode of 166 bp. Data supporting this view has been mainly acquired through…”
Get full text

Updates in the molecular pathology of non-small cell lung cancer by Paver, Elizabeth, O'Toole, Sandra, Cheng, Xin Min, Mahar, Annabelle, Cooper, Wendy A.

“…•Clinically established molecular genetic markers in NSCLC include EGFR, ALK, ROS1 and BRAF. Assessment of these molecular markers is required to identify…”
Get full text

Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee by Mino-Kenudson, Mari, Schalper, Kurt, Cooper, Wendy, Dacic, Sanja, Hirsch, Fred R, Jain, Deepali, Lopez-Rios, Fernando, Tsao, Ming Sound, Yatabe, Yasushi, Beasley, Mary Beth, Yu, Hui, Sholl, Lynette M, Brambilla, Elizabeth, Chou, Teh-Ying, Connolly, Casey, Wistuba, Ignacio, Kerr, Keith M, Lantuejoul, Sylvie

“…Immunotherapy including immune checkpoint inhibitors (ICIs) has become the backbone of treatment for most lung cancers with advanced or metastatic disease. In…”
Get more information

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma by Cooper, Wendy A, Tran, Thang, Vilain, Ricardo E, Madore, Jason, Selinger, Christina I, Kohonen-Corish, Maija, Yip, PoYee, Yu, Bing, O’Toole, Sandra A, McCaughan, Brian C, Yearley, Jennifer H, Horvath, Lisa G, Kao, Steven, Boyer, Michael, Scolyer, Richard A

“…Highlights • Programmed death-ligand 1 (PD-L1) is highly expressed in a low proportion of NSCLC. • High PD-L1 expression is associated with high tumor grade…”
Get full text

Dataset for the reporting of neoplasms of the heart, pericardium, and great vessels: recommendations from the International Collaboration on Cancer Reporting (ICCR) by Maleszewski, Joseph J., Basso, Cristina, Burke, Allen, Castonguay, Mathieu, Leduc, Charles, Tavora, Fabio, Sheppard, Mary, Suri, Rakesh, Judge, Meagan, Cooper, Wendy A.

“…The International Collaboration on Cancer Reporting (ICCR) was founded by major pathology organizations from around the world to produce internationally…”
Get full text

Extracellular matrix profiles determine risk and prognosis of the squamous cell carcinoma subtype of non-small cell lung carcinoma by Parker, Amelia L, Bowman, Elise, Zingone, Adriana, Ryan, Brid M, Cooper, Wendy A, Kohonen-Corish, Maija, Harris, Curtis C, Cox, Thomas R

“…Squamous cell carcinoma (SqCC) is a subtype of non-small cell lung cancer for which patient prognosis remains poor. The extracellular matrix (ECM) is critical…”
Get full text

Role of the ras-association domain family 1 tumor suppressor gene in human cancers by AGATHANGGELOU, Angelo, COOPER, Wendy N, LATIF, Farida

“…In recent years, the list of tumor suppressor genes (or candidate TSG) that are inactivated frequently by epigenetic events rather than classic…”
Get full text

Deep Learning-based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-resolution Computed Tomography by Walsh, Simon Lf, Mackintosh, John A, Calandriello, Lucio, Silva, Mario, Sverzellati, Nicola, Larici, Anna Rita, Humphries, Stephen M, Lynch, David A, Jo, Helen E, Glaspole, Ian, Grainge, Christopher, Goh, Nicole, Hopkins, Peter M A, Moodley, Yuben, Reynolds, Paul N, Zappala, Christopher, Keir, Gregory, Cooper, Wendy A, Mahar, Annabelle M, Ellis, Samantha, Wells, Athol U, Corte, Tamera J

“…RATIONALE Reliable outcome prediction in patients with fibrotic lung disease using baseline high-resolution computed tomography (HRCT) data remains…”
Get full text